Fate Therapeutics, Inc. (FATE)

Price$1.98

Value ScoreD

Growth ScoreF

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)65.76%

Price vs S&P 500 (4W)-17.15%

VGM Score41.03

Market Capitalization$230.79M

All Metrics

Book Value / Share (Quarterly)$1.55

P/TBV (Annual)0.48x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-58.98%

Cash Flow / Share (Quarterly)$-0.93

Price vs S&P 500 (YTD)93.88%

Net Profit Margin (TTM)-2056.79%

EPS (TTM)$-1.09

10-Day Avg Trading Volume5.60M

EPS Excl Extra (TTM)$-1.09

Revenue Growth (5Y)-26.71%

EPS (Annual)$-1.15

ROI (Annual)-62.60%

Net Profit Margin (5Y Avg)-868.65%

Cash / Share (Quarterly)$1.50

Revenue Growth QoQ (YoY)-20.26%

ROA (Last FY)-42.74%

Revenue Growth TTM (YoY)-52.64%

EBITD / Share (TTM)$-1.06

ROE (5Y Avg)-51.48%

Operating Margin (TTM)-2207.47%

Cash Flow / Share (Annual)$-0.97

P/B Ratio1.28x

P/B Ratio (Quarterly)0.78x

Net Income / Employee (Annual)$-846,700

EV / Revenue (TTM)31.95x

Net Interest Coverage (TTM)-2.83x

ROA (TTM)-39.39%

EPS Incl Extra (Annual)$-1.15

Current Ratio (Annual)5.79x

Quick Ratio (Quarterly)5.72x

3-Month Avg Trading Volume2.47M

52-Week Price Return47.76%

Revenue / Employee (TTM)$39,200

Tangible BV / Share (Quarterly)$4.09

P/S Ratio (Annual)34.73x

Asset Turnover (Annual)0.02x

52-Week High$2.88

Operating Margin (5Y Avg)-954.74%

EPS Excl Extra (Annual)$-1.15

CapEx CAGR (5Y)3.84%

Tangible BV CAGR (5Y)44.36%

26-Week Price Return73.68%

Quick Ratio (Annual)5.69x

13-Week Price Return43.48%

Total Debt / Equity (Annual)0.05x

Current Ratio (Quarterly)5.85x

Enterprise Value$201.78M

Revenue / Share Growth (5Y)-31.89%

Asset Turnover (TTM)0.02x

Book Value / Share Growth (5Y)-16.35%

Revenue / Employee (Annual)$41,300

Pretax Margin (Annual)-2051.08%

Cash / Share (Annual)$1.77

3-Month Return Std Dev119.60%

Net Income / Employee (TTM)$-806,900

ROE (Last FY)-65.79%

Net Interest Coverage (Annual)-2.02x

EPS Basic Excl Extra (Annual)$-1.15

Receivables Turnover (TTM)4.06x

Total Debt / Equity (Quarterly)0.06x

EPS Incl Extra (TTM)$-1.09

Receivables Turnover (Annual)2.58x

ROI (TTM)-56.96%

P/S Ratio (TTM)36.54x

Pretax Margin (5Y Avg)-868.65%

Revenue / Share (Annual)$0.06

Tangible BV / Share (Annual)$4.97

Price vs S&P 500 (52W)23.40%

Year-to-Date Return102.04%

5-Day Price Return-27.74%

EPS Normalized (Annual)$-1.15

ROA (5Y Avg)-35.95%

Net Profit Margin (Annual)-2051.08%

Month-to-Date Return-30.28%

Cash Flow / Share (TTM)$-1.58

EBITD / Share (Annual)$-1.13

Operating Margin (Annual)-2222.45%

LT Debt / Equity (Annual)0.01x

ROI (5Y Avg)-50.65%

LT Debt / Equity (Quarterly)0.01x

EPS Basic Excl Extra (TTM)$-1.09

P/TBV (Quarterly)0.58x

P/B Ratio (Annual)0.55x

Pretax Margin (TTM)-2056.79%

Book Value / Share (Annual)$1.80

Price vs S&P 500 (13W)35.22%

Beta2.59x

Revenue / Share (TTM)$0.05

ROE (TTM)-58.89%

52-Week Low$0.91

vGradeD

gGradeF

mGradeB

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.26est. -0.29

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

3.89

Industry Peers — Biological Products(178)

Symbol	Value Score	Growth Score	Momentum Score	Price
FATEFate Therapeutics, Inc.	D	F	B	$1.98
AMGNAmgen Inc	C	C	C	$349.58
GILDGilead Sciences Inc	C	B	C	$129.16
ARGXargenx SE American Depositary Shares	D	A	B	$891.32
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$149.23
BIIBBiogen Inc. Common Stock	B	D	B	$195.34
BNTXBioNTech SE American Depositary Share	C	C	D	$88.08
MRNAModerna, Inc. Common Stock	C	B	B	$47.44
NBIXNeurocrine Biosciences Inc	C	B	B	$163.88
EXELExelixis Inc	C	B	B	$52.70
KRYSKrystal Biotech, Inc. Common Stock	D	B	A	$301.00

About

Fate Therapeutics is a clinical-stage biopharmaceutical company developing cell-based immunotherapies targeting cancer and autoimmune disorders. The platform uses engineered natural killer and T cells derived from clonal master iPSC lines, alongside immunoregulatory candidates designed to prevent serious treatment complications.